Sign in
Taking peopleNo phase

Maximal Medical Treatment of Intracerebral Haemorrhage Pilot Trial - MAX-ICH Pilot Trial

Key facts

Who runs it
Insel Gruppe AG, University Hospital Bern
Where
Switzerland1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
50 people, planned
Started
7 Aug 2025
Expected to end
30 Nov 2028
Type of study
Interventional, 2 groups
Treatments tested
  • MAX-ICH care bundle
  • Standard of care
Record updated
2 July 2026

Who can take part

Age
18 years to 100 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Symptomatic imaging proven diagnosis of non-traumatic ICH
  • Vascular imaging (MR-/CT-angiogram or DSA) on admission to rule out high suspicion of macrovascular bleeding source
  • Enrolment no later than 6 hours of symptom onset
  • Age >18 years, no upper age limit
  • Informed consent as documented by signature or fulfilling the criteria for emergency consent/ deferral consent

Who cannot take part

  • Palliative care/comfort therapy decision in the emergency department
  • Active participation in another drug or devices trial concurrently
  • ICH due to trauma (major head trauma <24 hours of symptom onset causing loss of consciousness and thought to be sufficient to have caused the intracerebral bleeding)
  • High suspicion of ICH due to arteriovenous malformation (AVM), aneurysm or sinus-venous-thrombosis confirmed by neuroimaging, brain tumor, vasculitis, RCVS/PRES or system disease (liver disease, inherit coagulopathy)
  • Contraindications against Clevidipine (allergy to soja, lipid metabolism defect or known severe aortic stenosis)
  • Severe ICH (haematoma volume >60ml or GCS <8)
  • Haematoma evacuation or decompressive craniectomy within 72 hours planned or highly likely (isolated EVD is not an exclusion criterion)
  • Severe pre-morbid disability [modified Rankin scale (mRS) is ≥4]
  • Contraindication against the use of tranexamic acid
  • Female patient that are either pregnant or breastfeeding

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 100 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The MAX-ICH pilot trial is a phase-II study aimed at assessing the feasibility and safety of a comprehensive care bundle for patients with intracerebral hemorrhage (ICH). This "maximal medical treatment" approach combines advanced interventions like intensive blood pressure control, rapid anticoagulation reversal, and tranexamic acid administration to potentially improve outcomes. The primary objective is to evaluate recruitment feasibility over 12 months, while secondary objectives include protocol adherence, safety monitoring, and the exploration of clinical outcomes. The study focuses on the critical first 72 hours of care to determine if this approach can be effectively implemented in clinical practice.

The 2 groups in the trial

  • Control arm (usual care)Other group

    Control group is treated according to local standard of care

    Treatment: Standard of care

  • Experimental arm (MAX-ICH care bundle)Treatment being tested

    Experimental group is treated according MAX-ICH care bundle

    Treatment: MAX-ICH care bundle

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT06648369, who can take part
Record updated
2 July 2026